Genmab — November 2018

[Bulder]

Hvad mener du om amg 420, Solsen?

[Solsen]

Nu har de andet end BB21217

[Solsen]

Den er lidt sværere. Den høje dosering ser interessant ud. Men der skal noget mere tid til at bedømme den. Men skal analyseres nærmere. Dosis kunne være en begrænsning idet de har ramt loftet i 800 gruppen.

[Solsen]

..og så er indgivelsen grundet halvveringstiden jo selvsagt et stort problem.

[E_L]

Is it fair to assume that Griffin patients are healthier than some of the ohther studies we have seen because the patients are transplant eligible?

[Solsen]

Jeg synes begge stoffer er langt fra nogen der kan true Dara sc i firstline, hvor pengene ligger.

[Solsen]

Gad vide hvad omkostningen ved CyBor+D er i forhold til DRd ?

[Solsen]

I think your assumptions are right EL.

[E_L]

because it looks good, no? I mean, it is only on those first 16 patients so far, but looks very promissing, but a different set of patients can make a difference offcourse

[E_L]

and agree, looking forward to CAR-t comments in the next few days, could be important for Genmab sentiment

[bibob]

Se lige denne overskrift på Børsen. Danske bank og Genmab nævnt med fede typer , men ikke eet ord om Genmab i deres skriv. Latterligt. https://penge.borsen.dk/artikel/1/371553/markedet_lukker_danske_bank_og_genmab_i_top_-_coloplast_ender_med_fald_paa_37_pct.html

[bibob]

De kan virkelig ikke lide Genmab amatører.

[bibob]

GM - amatører

[Solsen]

NBI i +3,5% - har markedet altid ret. Bindegale udsving.

[transalp]

Enig.. jeg var da ved at gå i chok, da gen ab og dara blev nævnt i DR pressen da MAIA resultater kom.. ret vildt..

[bibob]

GMXAY + 5,71.

[Bulder]

E L: From Lyra: After induction, pts could undergo autologous stem cell transplantation (ASCT) - so they were also candidates. I don't think more frail than Griffin pts.

[Bulder]

The same goes for the small Irish cybord study: newly diagnosed MM (NDMM) pts eligible for ASCT

[Bulder]

The excitement in the conclusion is modest: Dara-CyBorD was active and well tolerated

[Bulder]

I'll ask Winkel if the results are worth a large phase 3 study.